Review desk · field journal

AssaygateGeneticSignal

Executive Summary The United States genetic-testing market was valued at roughly $11.71 billion in 2024, projected to reach $14.25 billion in 2025 and $39.25 billion by 2030 at a 22.5% CAGR, with next-generation sequencing (NGS) already the largest single technology segment (Grand View Research, "Genetic Testing Market Size & Share Report, 2030").

assaygatelabprepayerauthorizationgate

Who this is for

A precise operating owner, not a generic audience.

Responsible buyer

Target Buyer Attribute Detail Primary buyer / economic decision-maker VP of Revenue Cycle / Director of Billing & Reimbursement at an independent or regional CLIA/CAP-accredited molecular or genetic-testing laboratory Co-buyer / influencer Lab Director (CLIA-required medical/laboratory director) for clinical-workflow sign-off; CFO for contract approval on labs above ~$20M revenue ICP firmographics Independent/regional reference lab or lab-services company performing 500-10,000+ genetic/molecular tests per month across multiple commercial payers (hereditary cancer, pharmacogenomics, NIPT/carrie

Cost of the gap

The Painful Problem An independent molecular/genetic-testing lab commits real cost — reagents, sequencing capacity, technologist time — the moment it accessions a specimen and begins a run, well before it knows whether the claim will be reimbursed.

Outcome

The Outcome We Sell A specialist-released Run / Hold / Escalate clearance decision for every payer-covered genetic/molecular test order, delivered before the specimen consumes sequencing capacity — not a dashboard the lab's RCM staff must operate, and not a general-purpose prior-authorization tool they must configure themselves. For orders requiring notification or prior authorization, AssayGate Clear also delivers the completed, payer-specific submission package and tracks it to a decision. For claims denied despite a documented clearance, AssayGate Clear delivers an evidence-attached appeal packet.

Decision rule

Proceed only when the source record, service boundary, responsible reviewer, and release criteria can be named before work begins.

Method

The work moves through visible states.

  1. ScopeService Delivery Workflow Order intake (batch upload or LIS/API export) → AI extraction and normalization of diagnosis/code/payer data → AI policy match against the current payer matrix with confidence scoring → specialist review/release of any Hold/Escalate determination → for cleared-to-run orders, immediate Run signal returned to the lab within the specimen-accessioning window (target: same business day) → for Hold/Escalate orders, AI-drafted submission package assembled from existing physician documentation, specialist-reviewed and transmitted to the payer → status tracked to a payer decision, with automated escalation on stale/overdue requests → if a claim is later denied despite a documented clearance, an evidence-attached appeal packet is drafted and specialist-reviewed → monthly payer-matrix refresh cycle re-validates the policy knowledge base against newly published payer bulletins.
  2. CollectCollect only the source records required for the agreed work.
  3. NormalizeNormalize records and preserve file-level provenance.
  4. ValidateRun deterministic completeness and consistency checks.
  5. ResolveRoute missing, conflicting, or unsupported items to an exception queue.
  6. ReviewHave a qualified human review the release candidate.
  7. ReleaseRelease the final pack with an audit trail and correction path.

Engagement

Buy the reviewed outcome, with boundaries written down.

Pricing Evidence and Proposed Pricing Pricing-norm evidence: XiFin's data shows the average successful denial appeal recovers only $354, and the median charge exposed on a denied claim is $3,800 (Georgetown) — both figures anchor a per-order gate fee that must sit comfortably below the cost of a denial to be an obvious buy. Prior-authorization outsourcing guides (DataMatrix Medical, NeoWork, DrCatalyst, 2026 editions) describe outsourced PA work priced per case/request rather than hourly, consistent with the pricing model here.

Release package

  • The Outcome We Sell A specialist-released Run / Hold / Escalate clearance decision for every payer-covered genetic/molecular test order, delivered before the specimen consumes sequencing capacity
  • not a dashboard the lab's RCM staff must operate, and not a general-purpose prior-authorization tool they must configure themselves.
  • For orders requiring notification or prior authorization, AssayGate Clear also delivers the completed, payer-specific submission package and tracks it to a decision.
  • For claims denied despite a documented clearance, AssayGate Clear delivers an evidence-attached appeal packet.

Proof standard

Operating evidence: No verified cycle-time result is published yet. The first result will be calculated from accepted intake through qualified-human release.

Client evidence: No client identity or case narrative is published. A reference may appear only after written permission and factual review.

Volume evidence: No completed-client count is claimed. Counts will be published only after the delivery ledger and provider records reconcile.

Evidence room

Authority comes from traceable sources, not decorative claims.

Open the full canonical blueprint dossier

Service boundary

Automation prepares. A qualified human releases.

AssaygateGeneticSignal is an operational documentation and processing service operated by Your Deputy, Obuke LLC. It is not a law firm and does not provide legal, tax, medical, financial, or other licensed professional advice. Consumer and personal debt matters are not accepted. The client retains its licensed professionals and decision authority. Automation may organize and check records, but a qualified human must review and release every client deliverable. Minimum-necessary data handling and professional review apply.

  • Unsupported facts remain unresolved, never inferred into a client deliverable.
  • Jurisdiction-specific or licensed questions are routed to the client's professional.
  • Every correction retains the source, reviewer, version, and reason for change.

Questions

Know the limits before intake.

Is this legal or professional advice?

No. This is bounded operational documentation and processing support. Licensed judgment remains with the client and its professionals.

Does automation make the final decision?

No. It can organize records, run declared checks, and prepare an exception queue. A qualified human reviews and releases every deliverable.

Is a client portal or CRM already active?

This public site does not claim an active portal integration. Portal access is provisioned only after the relevant backend is configured and independently verified.

What happens when evidence conflicts?

The item is placed in an exception state with its sources and owner. It is not silently resolved or presented as verified.

Fit diagnostic

Send enough context to scope the next conversation—no sensitive files.

Do not submit protected health information, personal financial data, credentials, or confidential client records through this public page.